Lausanne, April 11th 2019 - Gnubiotics Sciences SA is a Swiss biotech company pioneering the development of products from complex microbiota accessible carbohydrates (MACs) as specialty ingredients for the global animal and human nutrition markets.

Gnubiotics announced its listing in the EU Feed Materials Register and commercial launch of its first-in class microbiome modulating prebiotic GNU100, for companion animal gut health. Gnubiotics’ GNU100 MAC is registered in Europe as an oligosaccharide-peptide complex with the objective to enhance microbiota restoration. As a result of its activity on specific commensals in the microbiome, GNU100 will also be studied to act as a weight control modulator.

GNU100 comprises of at least 30 different oligosaccharide structures that are functional mimics of Human Milk Oligosaccharides (HMOs). HMOs are oligosaccharides found naturally in animal and human breast milk and are key to the early development and maintenance of the immune system.

At Vitafoods Europe, Gnubiotics will host a presentation by Prof. Kelly Swanson of the University of Illinois-Urbana Champaign, titled “Modulatory Activity of Microbiota Accessible Carbohydrates” which will highlight GNU100 in vivo palatability data as well as the in vitro activity of GNU100 on key microbes beneficial to companion animal health Lactobacillus acidophilus, Akkermansia muciniphila and Bacteroides thetaiotaomicron.

“The global launch of GNU100 marks a milestone in our commitment to bringing the benefits of our pipeline of functional HMO mimics to companion animals” said JP Kunz, CEO at Gnubiotics.

Through the combination of advanced high-precision chemistry and genomic technologies, Gnubiotics aims to expand nutritional solutions, to meet consumer expectations for effective, natural and healthier foods and supplements for their companion animal.

To learn more about how GNU100 can benefit your consumers, please visit Gnubiotics Sciences at Vitafoods Europe in Geneva Palexpo, May 7 – 9, 2019, at booth #K85

>> Press Release

 

About Gnubiotics:

Gnubiotics Sciences SA is a biotech company founded in Switzerland, located at the Biopôle in Lausanne, Switzerland, to develop a platform to commercialize microbiota accessible carbohydrate (MAC) ingredients for the functional nutrition and the therapeutics markets. These MAC formulations mimic the natural diversity and complexity of Human Milk Oligosaccharides (HMOs) which are unique structures found in mothers’ milk and are crucial to early protection against infections and the immune development.
“GUT NATURALLY UNDERSTOOD” (GNU) became Gnubiotics raison-d’être with a goal to accelerate metabolic health in animals and humans. The company is developing a robust platform for selective microbiota modulation via natural mechanism of action with a rich pipeline in nutrition (Animal and Human) and later for medical food solutions. www.gnubiotics.com

Media contact information – Gnubiotics Sciences SA. Jean Philippe Kunz, CEO Email: jpkunz@gnubiotics.com